A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.
Advanced Malignant Neoplasm
DRUG: QLF31907|DRUG: Irinotecan|DRUG: Docetaxel
phase Ib: Dose-limiting toxicity(DLT), The DLT of QLF31907 combination therapy will be determined, 28 days|phase2: objective response rate(ORR), the ORR of QLF31907 combinaton therapy will be determined, up to 2 years
adverse events (AEs) of QLF31907 combination therapy, to evaluate the severity, incidence and causality of adverse events (AEs), up to 2 years|area under the concentration-time curve (AUC) of QLF31907, the area under the concentration-time curve (AUC) of QLF31907 will be determined, up to 2 years|Immunogenicity of QLF31907, the anti-drug antibody(ADA) against QLF31907 will be determined, up to 2 years|overall survival(OS), the OS of QLF31907 combination therapy will be determined, up to 2 years|maximum plasma concentration (Cmax) of QLF31907, the maximum plasma concentration (Cmax) of QLF31907 will be determined, up to 2 years
This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.